Studying the structure and regulation of soluble guanylyl cyclase.

Soluble guanylyl cyclase acts as the receptor for the signaling molecule nitric oxide. The enzyme consists of two different subunits. Each subunit shows the cyclase catalytic domain, which is also conserved in the membrane-bound guanylyl cyclases and the adenylyl cyclases. The N-terminal regions of the subunits are responsible for binding of the prosthetic heme group of the enzyme, which is required for the stimulatory effect of nitric oxide (NO). The five-coordinated ferrous heme displays a histidine as the axial ligand; activation of soluble guanylyl cyclase by NO is initiated by binding of NO to the heme iron and proceeds via breaking of the histidine-to-iron bond. Recently, a novel pharmacological and possibly physiological principle of guanylyl cyclase sensitization was demonstrated. The substance YC-1 has been shown to activate the enzyme independent of NO, to potentiate the effect of submaximally effective NO concentrations, and to turn carbon monoxide into an effective activator of soluble guanylyl cyclase.

[1]  G. Schultz,et al.  Stimulation of soluble guanylate cyclase by superoxide dismutase is mediated by NO. , 1998, The Biochemical journal.

[2]  C. Harteneck,et al.  Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. , 1998, The Biochemical journal.

[3]  M. Marletta,et al.  Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. , 1998, Chemistry & biology.

[4]  Y. Zhao,et al.  Identification of histidine 105 in the beta1 subunit of soluble guanylate cyclase as the heme proximal ligand. , 1998, Biochemistry.

[5]  Yunde Zhao,et al.  Localization of the heme binding region in soluble guanylate cyclase. , 1997, Biochemistry.

[6]  S R Sprang,et al.  Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. , 1997 .

[7]  D. Magde,et al.  Dissociation of nitric oxide from soluble guanylate cyclase. , 1997, Biochemical and biophysical research communications.

[8]  R. Danziger,et al.  The beta2 subunit inhibits stimulation of the alpha1/beta1 form of soluble guanylyl cyclase by nitric oxide. Potential relevance to regulation of blood pressure. , 1997, The Journal of clinical investigation.

[9]  T. Kitagawa,et al.  Purification of bovine soluble guanylate cyclase and ADP-ribosylation on its small subunit by bacterial toxins. , 1997, Journal of biochemistry.

[10]  R. Fischmeister,et al.  A comparative study of the effects of three guanylyl cyclase inhibitors on the L‐type Ca2+ and muscarinic K+ currents in frog cardiac myocytes , 1997, British journal of pharmacology.

[11]  D. Magde,et al.  Kinetics of nitric oxide dissociation from five- and six-coordinate nitrosyl hemes and heme proteins, including soluble guanylate cyclase. , 1997, Biochemistry.

[12]  S. Kuo,et al.  YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. , 1997, European journal of pharmacology.

[13]  G. Schultz,et al.  Functions of conserved cysteines of soluble guanylyl cyclase. , 1997, Biochemistry.

[14]  R. Busse,et al.  Effect of YC‐1, an NO‐independent, superoxide‐sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators , 1997, British journal of pharmacology.

[15]  G. Schultz,et al.  Sensitizing soluble guanylyl cyclase to become a highly CO‐sensitive enzyme. , 1996, The EMBO journal.

[16]  G. Schultz,et al.  A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. , 1996, European journal of biochemistry.

[17]  C. Dessauer,et al.  Purification and Characterization of a Soluble Form of Mammalian Adenylyl Cyclase* , 1996, The Journal of Biological Chemistry.

[18]  G. Schultz,et al.  Positive effects of pollution? , 1996, Nature.

[19]  B. Mayer,et al.  Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. , 1996, Molecular pharmacology.

[20]  B. Mayer,et al.  Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. , 1996, The Journal of pharmacology and experimental therapeutics.

[21]  M. Marletta,et al.  Heme stoichiometry of heterodimeric soluble guanylate cyclase. , 1995, Biochemistry.

[22]  G. Schultz,et al.  Functional Domains of Soluble Guanylyl Cyclase (*) , 1995, The Journal of Biological Chemistry.

[23]  S. Kuo,et al.  YC‐1 inhibited human platelet aggregation through NO‐independent activation of soluble guanylate cyclase , 1995, British journal of pharmacology.

[24]  S. Moncada,et al.  Molecular mechanisms and therapeutic strategies related to nitric oxide , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  C. Harteneck,et al.  A Variant of the α2 Subunit of Soluble Guanylyl Cyclase Contains an Insert Homologous to a Region within Adenylyl Cyclases and Functions as a Dominant Negative Protein (*) , 1995, The Journal of Biological Chemistry.

[26]  A. Gilman,et al.  Construction of a soluble adenylyl cyclase activated by Gs alpha and forskolin. , 1995, Science.

[27]  E. Wilson,et al.  Identification of sequences mediating guanylyl cyclase dimerization. , 1995, Biochemistry.

[28]  U. Walter,et al.  NO at work , 1994, Cell.

[29]  M. Marletta,et al.  Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. , 1994, Biochemistry.

[30]  D. Garbers,et al.  Dominant negative mutants of nitric oxide-sensitive guanylyl cyclase. , 1994, The Journal of biological chemistry.

[31]  T. Lincoln,et al.  Intracellular cyclic GMP receptor proteins , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  G. Schultz,et al.  Molecular cloning and expression of a new α‐subunit of soluble guanylyl cyclase Interchangeability of the α‐subunits of the enzyme , 1991 .

[33]  F. Murad,et al.  Expression of soluble guanylate cyclase activity requires both enzyme subunits. , 1991, Biochemical and biophysical research communications.

[34]  D. Garbers,et al.  A new form of guanylyl cyclase is preferentially expressed in rat kidney. , 1990, Biochemistry.

[35]  G. Schultz,et al.  Expression of soluble guanylyl cyclase , 1990, FEBS letters.

[36]  B. Brüne,et al.  Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. , 1990, European journal of biochemistry.

[37]  G. Schultz,et al.  Purification of soluble guanylyl cyclase from bovine lung by a new immunoaffinity chromatographic method. , 1990, European journal of biochemistry.

[38]  J. Garthwaite,et al.  Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain , 1988, Nature.

[39]  F. Murad,et al.  Cyclic GMP synthesis and function. , 1987, Pharmacological reviews.

[40]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[41]  F. Murad,et al.  Soluble guanylate cyclase from rat lung exists as a heterodimer. , 1986, The Journal of biological chemistry.

[42]  G. Schultz,et al.  Soluble guanylate cyclase purified from bovine lung contains heme and copper , 1981, FEBS letters.

[43]  D. Garbers Purification of soluble guanylate cyclase from rat lung. , 1979, The Journal of biological chemistry.